Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Roflumilast
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Arcutis Biotherapeutics
Deal Size : $40.0 million
Deal Type : Collaboration
Arcutis and Sato Announce Strategic Collaboration for Topical Roflumilast in Japan
Details : The collaboration aims to enable Sato to concentrate on the development, manufacturing, and commercialization of topical Zoryve (roflumilast) in Japan. It is used in the treatment of Plaque Psoriasis.
Product Name : Zoryve
Product Type : Other Small Molecule
Upfront Cash : $25.0 million
February 28, 2024
Lead Product(s) : Roflumilast
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Arcutis Biotherapeutics
Deal Size : $40.0 million
Deal Type : Collaboration
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : EPI Health
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Details : Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trial...
Product Name : Rhofade
Product Type : Other Small Molecule
Upfront Cash : $5.0 million
December 21, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : EPI Health
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Luliconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 08, 2021
Lead Product(s) : Luliconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable